Net profit before taxes saw a 9.8% year-on-year (YoY) increase at $41.1m (AED151m) whilst the group’s revenue climbed 14% YoY in Q3, reaching $353.9m (AED1.3b).
LANCASTER, PA — Emerald Advisers, in collaboration with F/m Investments, has introduced the F/m Emerald Life Sciences Innovation ETF (LFSC), now available on the Nasdaq Stock Market under the ticker ...
The Company submitted an sNDA for ZORYVE foam for scalp and body psoriasis to the FDA based on the positive results from the pivotal ARRECTOR Phase 3 trial and a Phase 2b trial, which was accepted by ...
Investigations revealed that a French pharmaceutical company fell victim to a business e-mail impersonation scam by the syndicate in March 2020. The firm transferred more than $10 million for what ...
Ultragenyx Pharmaceutical RARE during the recent three months, expressing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, showcasing how ...